Status of Anaplastic Lymphoma Kinase (ALK) in Malignant Mesothelioma

被引：0

作者：

Varesano, Serena ^{[1
]}

Leo, Claudio ^{[1
]}

Boccardo, Simona ^{[1
]}

Salvi, Sandra ^{[1
]}

Truini, Mauro ^{[1
]}

Ferro, Paola ^{[3
]}

Fedeli, Franco ^{[3
]}

Canessa, Pier Aldo ^{[4
]}

Dessanti, Paolo ^{[3
]}

Pistillo, Maria Pia ^{[2
]}

Roncella, Silvio ^{[3
]}

机构：

[1] Natl Inst Canc Res, Div Histopathol & Cytopathol, Ist Ricovero & Cura Carattere Sci Azienda Osped U, Genoa, Italy

[2] Natl Inst Canc Res, Unit Tumor Epigenet, Ist Ricovero & Cura Carattere Sci Azienda Osped U, Genoa, Italy

[3] Azienda Sanit Locale 5, Div Histopathol & Cytopathol, La Spezia, Italy

[4] Azienda Sanit Locale 5, Div Pneumol, La Spezia, Italy

来源：

ANTICANCER RESEARCH | 2014年 / 34卷 / 05期

关键词：

Anaplastic lymphoma kinase; crizotinib; fluorescent in situ hybridization; immunohistochemistry; malignant mesothelioma; targeted therapy; CELL LUNG-CANCER;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Malignant mesothelioma (MM) is a particularly aggressive type of primary tumor, associated with exposure to asbestos, and characterized by high mortality. To date, there is no curative therapy for MM. The receptor anaplastic lymphoma kinase (ALK) was found to be mutated in many cases of cancer and used as a target in biological therapies. We investigated whether this pharmacological treatment could also be applicable to MM. Materials and Methods: The state of ALK was analyzed by immunohistochemistry and fluorescent in situ hybridization in 63 MM tissue specimens. Results: None of the 63 MM samples showed overexpression or translocation of ALK. Conclusion: Our preliminary data exclude the utility of analysis of the ALK gene in MM and suggest that ALK inhibitor therapy is not applicable to MM.

引用

页码：2589 / 2592

页数：4

共 50 条

[41] Anaplastic Lymphoma Kinase (ALK)-negative systemic anaplastic large cell lymphoma presenting as zosteriform skin nodules
Ahuja, Rhea
Patel, Varniraj
Mallick, Saumayaranjan
Damle, Nishikant
Sharma, Atul
Gupta, Vishal
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2024, 90 (03): : 358 - 362
[42] Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors
Lovly, C. M.
de Stanchina, E.
Chen, H.
Liang, C.
Pao, W.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, Robert, Jr.
PHARMACOLOGICAL RESEARCH, 2013, 68 (01) : 68 - 94
[44] Timely topic: Anaplastic lymphoma kinase (ALK) spreads its influence
Cheuk, W
Chan, JKC
PATHOLOGY, 2001, 33 (01) : 7 - 12
[45] Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers
Kinoshita, Kazutomo
Oikawa, Nobuhiro
Tsukuda, Takuo
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 47, 2012, 47 : 281 - 293
[46] The anaplastic lymphoma kinase (ALK) gene is associated with schizophrenia in a Chinese population
Luan, Zhilin
Zhang, Dai
PSYCHIATRY RESEARCH, 2017, 258 : 612 - 613
[47] LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor
Chen, Jianyong
Jiang, Cheng
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (14) : 5673 - 5674
[48] Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
Huang, Hao
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
[49] The Association between the Percentage of Anaplastic Lymphoma Kinase(ALK)-Positive Cells and Efficacy of ALK Inhibitor
Tanaka, Tae
Yoshioka, Hiroshige
Haratani, Koji
Hayashi, Hidetoshi
Okamoto, Kunio
Kaneda, Toshihiko
Yokoyama, Toshihide
Takeda, Masayuki
Kaneda, Hiroyasu
Nakagawa, Kazuhiko
Ishida, Tadashi
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1162 - S1162
[50] Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
Nakajima, Masayuki
Uchiyama, Naoki
Shigemasa, Rie
Matsumura, Takeshi
Matsuoka, Ryota
Nomura, Akihiro
INTERNAL MEDICINE, 2016, 55 (21) : 3151 - 3153

← 1 2 3 4 5 →